143 related articles for article (PubMed ID: 21886520)
1. Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases.
Hoverman JR; Cartwright TH; Patt DA; Espirito JL; Clayton MP; Garey JS; Kopp TJ; Kolodziej M; Neubauer MA; Fitch K; Pyenson B; Beveridge RA
J Oncol Pract; 2011 May; 7(3 Suppl):52s-9s. PubMed ID: 21886520
[TBL] [Abstract][Full Text] [Related]
2. Pathways, outcomes, and costs in colon cancer: retrospective evaluations in 2 distinct databases.
Hoverman JR; Cartwright TH; Patt DA; Espirito JL; Clayton MP; Garey JS; Kopp TJ; Kolodziej M; Neubauer MA; Fitch K; Pyenson B; Beveridge RA
Am J Manag Care; 2011 May; 17 Suppl 5 Developing():SP45-52. PubMed ID: 21711077
[TBL] [Abstract][Full Text] [Related]
3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data.
Hess LM; Michael D; Mytelka DS; Beyrer J; Liepa AM; Nicol S
Gastric Cancer; 2016 Apr; 19(2):607-615. PubMed ID: 25792290
[TBL] [Abstract][Full Text] [Related]
5. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
6. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the Anticancer Treatment Trajectory and Pattern in Patients Receiving Chemotherapy for Cancer Using Harmonized Observational Databases: Retrospective Study.
Jeon H; You SC; Kang SY; Seo SI; Warner JL; Belenkaya R; Park RW
JMIR Med Inform; 2021 Apr; 9(4):e25035. PubMed ID: 33720842
[TBL] [Abstract][Full Text] [Related]
9. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
11. Cost differential by site of service for cancer patients receiving chemotherapy.
Hayes J; Hoverman RJ; Brow ME; Dilbeck DC; Verrilli DK; Garey J; Espirito JL; Cardona J; Beveridge R
Am J Manag Care; 2015 Mar; 21(3):e189-96. PubMed ID: 26014306
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
13. Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations.
Mahé I; Mayeur D; Krakowski I
Support Care Cancer; 2016 Oct; 24(10):4105-12. PubMed ID: 27146390
[TBL] [Abstract][Full Text] [Related]
14. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
[TBL] [Abstract][Full Text] [Related]
15. Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database.
Karve S; Lorenzo M; Liepa AM; Hess LM; Kaye JA; Calingaert B
J Gastric Cancer; 2015 Jun; 15(2):87-104. PubMed ID: 26161282
[TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
17. Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.
Duh MS; Reynolds Weiner J; Lefebvre P; Neary M; Skarin AT
Curr Med Res Opin; 2008 Apr; 24(4):967-74. PubMed ID: 18282373
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and direct medical costs of metastatic colorectal cancer patients: a retrospective study of electronic medical records from urban China.
Shen L; Li Q; Wang W; Zhu L; Zhao Q; Nie Y; Zhu B; Ma D; Lin X; Cai X; Fang W; Peng C; Chen Y; Fang H; Yin Z; Li H; Wang N; Xu R
J Med Econ; 2020 May; 23(5):456-463. PubMed ID: 31950863
[No Abstract] [Full Text] [Related]
20. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
